Abstract
We briefly outline the rationale for employing positron emission tomography (PET), using the ligand [11C](R)-PK11195, the binding site for which is highly expressed by activated microglia, in order (a) to detect in vivo neuroinflammatory changes occurring in a variety of brain diseases and at different disease stages and (b) to monitor the progression of neuroinflammation as a generic in vivo marker of 'disease activity'. The use of [11C](R)-PK11195 PET is described as a systematic attempt at measuring the emerging phenomenology of tissue pathology itself - as opposed to measuring, for example, the loss of neuronal function or structure - and as a proof of principle for the clinical utility of imaging glial cells in vivo. © 2002 Elsevier Science B.V./ECNP All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 581-586 |
Number of pages | 5 |
Journal | European Neuropsychopharmacology |
Volume | 12 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 2002 |
Keywords
- [11C](R)-PK11195
- Neuroinflammation
- Positron emission tomography